### Rujukan Kami: (68) MOH/HQ/P/IKLAN-SH/2025

## LAMPIRAN 2

BIL	Quotation Reference	Description	Advertisement Date	Closing Date (Not Later Than 09.00AM)	Quotation Fee	Requesting Department	Focal Person
2	PPS/QTN/52/2025)	1/ BETAMETHASONE SODIUM PHOSPHATE 0.1% AND NEOMYCIN SULFATE 0.5% EYE/EAR DROP.  2/ GRISEOFULVIN 125MG ORAL SOLID PREPARATION PREFERABLY TABLET	06/05/2025	24/05/2025	\$5.00	JABATAN PERKHIDMATAN FARMASI KEMENTERIAN KESIHATAN	LENNY MARLIANI BINTI HAJI RAMLI PHARMACIST DRUG PURCHASING SECTION TEL: 2393298 ext. 228

QTN REF: PPS/QTN/ 52 /2025

#### SUPPLY AND DELIVERY OF MEDICINES FOR THE DEPARTMENT OF PHARMACEUTICAL SERVICES

NO	DESCRIPTION OF ITEM	QUANTITY	BRAND	MANUFACTURER AND COUNTRY OF ORIGIN	PRICE AND PACK SIZE	TOTAL PRICE
1.	Betamethasone sodium phosphate 0.1% and neomycin sulfate 0.5% eye/ear drop	500 x <b>12'</b> s				
2.	Griseofulvin 125mg oral solid preparation preferably tablet	300 x 100's				
First ord	Y PERIOD: er 2 months, subsequent order 1 month eipt of purchase order					
DELAY A If the Sup from the	ND LIQUIDATED DAMAGES:  oplier fails or is unable to deliver the Goods or  Supplier by way of liquidated damages for ea  of the delayed delivery, provided that the tota	ch day of such delay, a	sum of equal to one pe	rcent (1%) of the price of the	Goods as stated in the r	
which no	ALIDITY: tation shall remain valid for 6 MONTHS from a supplier may withdraw his/her quotation. \ hent i.e. 6 months, the LONGER VALIDITY PE	Where the price validit	y differs from that requ			

### QTN REF: PPS/QTN/ 52 /2025

### SUPPLY AND DELIVERY OF MEDICINES FOR THE DEPARTMENT OF PHARMACEUTICAL SERVICES

		TERMS AND CONDITIONS	
a.	Vendor must be registered with the Ministry of Health	Acknowledgement:	Company's Official Stamp
b.	Please complete the QUOTATION FORM including the USER REQUIREMENT FORM. Submission of incomplete forms may cause DISQUALIFICATION OF QUOTATION	Company Ref. No.:	
C	Each vendor is required to quote ONE BRAND WITH ONE PRICE ONLY for each item.	I hereby certify the above quote to be correct.  Signature:	
d,	Delivery Period:  FIRST ORDER 2 MONTHS, SUBSEQUENT ORDER 1 MONTH	Name:	
е.	PRICE VALIDITY: The quotation shall remain valid for 6 MONTHS from the	Designation:	
	final date for the submission of the quotation, during which no supplier may withdraw his/her quotation. Where the price validity differs from that required by the Government i.e. 6 months, the LONGER VALIDITY PERIOD will be taken as the final validity period.	Date:	
f.	LETTER OF UNDERTAKING (LOU):  If any of the Goods to be supplied have an expiry date of		
	less than 18 months upon delivery, vendor is required to provide letter of undertaking. The Supplier hereby		

To you be seen to the seen to	undertakes to: (i) replace any of the Goods with fresh, new stock; or (ii) issue credit note equivalent to the value of the expired Goods.	
g.	Please do not use correction tape or pen/fluid for amendment	

### SAMPLE SUBMISSION FORM

To:	The Pharmacist Pharmacy Procurement Section,		ate:			
	3 <sup>rd</sup> Floor, Department of Pharmaceutical Servic Spg 433, Rimba Highway, Kg Madaras Ministry of Health, Negara Brunei Darussalam		our Ref:			
SUB	SUBMISSION OF SAMPLES FOR QUOTATION REF: PPS / QTN / 52 / 2025					
	nit sample to Pharmacy Procurement Section in of quotation advertisement.	o later than FOU	R WEEKS after	closing		
	ring to the above quotation reference, please see table below.	our feedback on	the sample subn	niśsion		
NO	(TEM	SAMPLE SUBMITTED (indicate with v')	SAMPLE NOT SUBMITTED (indicate X with reason)	property and provide all controls of the control of		
1/	Betamethasone sodium phosphate 0.1% and neomycin sulfate 0.5% eye/ear drop			A Charle Colonial and a charle		
2/	Griseofulvin 125mg oral solid preparation preferably tablet	100 market   100 mil   100	20 A 10 A	Andrew Programmer Control		
be co	nsidered unless they fulfill the criteria for sample of some some some some some some some some		de Official Character			
		Company	y's Official Stamp	)		
Name Positi Comp	on:					
	FOR OFFICIAL L	JSE				
Samp	le received by:					
Date	received:					

QTN REF: PPS/QTN/52/2025

No	Requirements	Enter Response Here
1	Sample	
	Vendor is required to submit sample in untampered original pack including package insert and Summary of Product Characteristics (in English)	
STATE OF THE PROPERTY OF THE P	For Controlled drugs and Psychotropics: In the event that sample cannot be submitted, photos and/or artwork are required. See 'Presentation'.	
2	Presentation	
	Vendor is to submit:  i. Clear colour-printed photo of the product offered with company's official stamp. Photo must show label details of the primary and secondary packaging from all sides/angles including name / brand of item, strength and form / preparation.	
	<ul> <li>ii. High resolution photo of the following</li> <li>For tablets / capsules: <ul> <li>Appearance of individual tablets</li> <li>/ capsules;</li> <li>If the item is in strip pack, the back and front of the strip</li> </ul> </li> <li>For Injections: <ul> <li>Appearance of individual vial / ampoule / syringe</li> </ul> </li> </ul>	
3	Registration with Brunei Darussalam Medicines Control Authority (BDMCA)	
	A copy of any of the following:	

4	Manufacturer details	
	Please provide manufacturer details with	
	supporting documents.	
	If manufacturer details are not available, please provide the following:	
real resource property (I.m. in.	Hardcopy of declaration letter from the principal to inform any issues related to product safety, quality and efficacy as a result of a recall by the manufacturer, wholesaler or Department of Health     A copy of the principal's wholesaler license.	
5	Shelf life	
	Please indicate the product shelf-life. Priority will be given to product with a minimum of 24 months.	
6	Storage condition	
The second secon	The storage labelling should be in accordance with the latest guideline on registration of medicinal products in Brunei Darussalam.	
7.7.7.7.6.7	Priority is given to products with specified storage conditions. Terms such as "ambient conditions", "room temperature" or "does not require any special storage condition" should be avoided unless stability studies are provided.	
7	Alcohol and animal content	
	Declaration of source of animal origin and/or	
	alcohol content (if any) is to be provided.	
8		
	Certificate of Analysis	
	A copy of the product's Certificate of Analysis (CoA) is to be submitted.	

T*************************************		
9	New Product	
	Where the product offered has never been supplied to the Ministry of Health, Brunei, detailed information on the product is to be submitted. The information required include, but not limited to, the following:	
	i. Bioequivalence studies (Generic products) and / or Clinical studies ii. Stability studies iii. Certificate of free sales iv. Certificate of Pharmaceutical Product (CPP) v. A copy of the Summary of Product Characteristics vi. Good Manufacturing Practice (GMP) certificate vii. Batch release certificate or certificate of origin (for blood products)	
10	Price Justification	
	Vendor is to submit letter of justification on price increase if the same product has been previous supplied to Ministry of Health from the same supplier / distributor.	
11	Local content & Tax Compliance Certificate	
:	Vendor is to provide a copy of the latest content of the company as well as the updated tax compliance certificate, if applicable	
12	Product Registration Number in any of the *benchmark/reference countries	
Activities in the contract of	If not registered with BDMCA, priority will be given to products which are registered in any of the benchmark/reference countries.	
de state grant de la companya de la	*The benchmark/reference countries are Australia, Canada, Malaysia, Singapore, United Kingdom, the United States of America, France, Sweden, Japan, Switzerland, Republic of Korea & European Union.	
L		

13	Pate	nt Declaration	
	1.	Vendors quoting generic products must provide an official declaration or confirmation from the Brunei's Intellectual Property Office verifying whether the innovator product is off-patent Vendors quoting innovator products must provide information on the patent status and expiry in Brunei.	